Home Cart Sign in  
Chemical Structure| 1416324-85-0 Chemical Structure| 1416324-85-0

Structure of CU-CPT22
CAS No.: 1416324-85-0

Chemical Structure| 1416324-85-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Selective toll-like receptor 1/2 (TLR1/2) inhibitor (IC50 = 0.58 μM). Exhibits no activity at TLR2/TLR6, TLR3, TLR4 and TLR7 or a panel of 10 representative kinases. Inhibits the release of proinflammatory cytokines TNF-α and IL-1β.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CU-CPT22

CAS No. :1416324-85-0
Formula : C19H22O7
M.W : 362.37
SMILES Code : O=C(C(C=C1O)=CC2=CC(OC)=C(O)C(O)=C2C1=O)OCCCCCC
MDL No. :MFCD26406409
InChI Key :UBQFTTUFRSSOHE-UHFFFAOYSA-N
Pubchem ID :71503400

Safety of CU-CPT22

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H334-H410
Precautionary Statements:P261-P273-P342+P311-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of CU-CPT22

pyroptosis
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW 264.7 macrophage cells 0.58 ± 0.09 µM Inhibits TLR1/2 signaling PMC3510333
HEK-hTLR2 reporter cells 8.0 ng/mL 20 hours To test the effectiveness of CU-CPT22 in blocking the SynO-TLR1/2 interaction, results showed that CU-CPT22 significantly decreased reporter activity. PMC4601639
Primary mouse microglia 80.0 ng/mL 2 hours To investigate the effect of CU-CPT22 on SynO-induced NF-κB nuclear translocation, results showed that CU-CPT22 significantly reduced NF-κB nuclear translocation. PMC4601639
RSC96 cells 1 µg/ml 24 hours To investigate the protective effect of CU-CPT22 on α-syn PFF-induced RSC96 cell damage, results showed that CU-CPT22 significantly reduced the loss of cell viability PMC10817950
HEK293-hTLR2 cells 1, 5, 10, 20 µM 16 hours CU-CPT22 inhibited Pam3CSK4-induced TLR2/1 heterodimerization PMC6073418
Raw264.7 cells 10 µM and 20 µM 16 hours CU-CPT22 significantly inhibited Pam3CSK4-induced TRL2/1 signaling PMC6073418

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice MPTP-induced Parkinson's disease model Injection 3 mg/kg Once daily for 35 days To investigate the protective effect of CU-CPT22 on MPTP-induced autonomic dysfunction, results showed that CU-CPT22 improved gastrointestinal symptoms, urinary frequency, and cardiovascular function PMC10817950
C57BL/6J mice MPTP-induced Parkinson’s disease model Intraperitoneal injection 3 mg/kg Administered 30 min prior to MPTP injection, lasted for 5 weeks CU-CPT22, as a TLR2 antagonist, ameliorated MPTP-induced motor dysfunction and nerve conduction damage, reduced p-α-syn accumulation and TLR2/NF-κB pathway activation PMC8511120
CD-1 male mice Cecal ligation and puncture (CLP) model Intraperitoneal injection 3 mg/kg/day 2 days CU-CPT22 attenuated sepsis-induced neuroinflammation and cognitive dysfunction PMC5902799

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.76mL

0.55mL

0.28mL

13.80mL

2.76mL

1.38mL

27.60mL

5.52mL

2.76mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories